A Prospective Study of Spasticity in Individuals With Multiple Sclerosis

Study Description

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This study is expected to contribute to the body of knowledge on the benefits of individuals with MS taking glatiramer acetate (Copaxone®). If patients have less spasticity when taking glatiramer acetate (Copaxone®), they may be more likely to have an improved quality of life.

The hypotheses for this study are:

1. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a decrease in spasticity.
2. Study participants who transition from interferon therapy to glatiramer acetate (Copaxone®) for a six month period will have a change in perceptions of the impact of spasticity on their lives.

Condition or disease
Spasticity

Detailed Description:

The purpose of this study is to determine if there is a change in spasticity and perceptions of the impact of spasticity in individuals with multiple sclerosis who transition from interferon to glatiramer acetate (Copaxone®).•

• Potential participants meeting the criteria will be identified by Shared Solutions and informed of the study. Interested individuals will contact the investigator either by email or telephone. Enrollment will continue until there are 110 participants starting glatiramer acetate (Copaxone®).
• Potential participants will be informed of the details of the study, eligibility will be confirmed, and participant's questions answered.
• The two study instruments and the sociodemographic questionnaire will be emailed or mailed via UPS along with an information letter. May be returned either via email, fax or UPS mail.
• At month 6 for each participant, the study instruments and sociodemographic questionnaire will be sent a second time and returned to the investigator.

Study Design

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Observational
Estimated Enrollment :	110 participants
Observational Model:	Cohort
Time Perspective:	Prospective
Official Title:	A Prospective Study of Spasticity in Individuals With Multiple Sclerosis in Transition From Interferon to Glatiramer Acetate (Copaxone®)
Study Start Date :	April 2010
Estimated Primary Completion Date :	September 2012
Estimated Study Completion Date :	December 2012

Groups and Cohorts

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort
Individuals with Multiple Sclerosis

Outcome Measures

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Multiple Sclerosis Spasticity Scale [ Time Frame: Administered at 6 month follow-up ]

Secondary Outcome Measures :

1. Performance Scales (Measure of Disability) [ Time Frame: Administered at 6 month follow-up ]

Eligibility Criteria

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Individuals with Multiple Sclerosis living in the community

Criteria

Inclusion Criteria:

• Stopped interferon (beta-1a or beta-1b) within the past 30 days
• About to start or started glatiramer acetate (Copaxone®) within the past 21 days.
• At least 18 years of age
• Has spasticity at the beginning of the study
• Able to ambulate with unilateral support or without support
• Understands, speaks and reads English

Exclusion Criteria:

• Severe Gait Disability or Total Gait Disability

Contacts and Locations

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Missouri
Shared Solutions Call Center
Kansas City, Missouri, United States, 64131

Sponsors and Collaborators

Fraser, Cira, Ph.D., RN, ACNS-BC

Investigators

Principal Investigator:	Cira Fraser, PHD	Monmouth University

More Information

Go to 

Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications:

Meca-Lallana, J.E., Amorin-Diaz, M., Martinez-Navarro, M.L. & Fernandez- Barreiro, A. (2008). Spasticity in multiple sclerosis: A pilot study to evaluate the efficacy of glatiramer acetate. Multiple Sclerosis, 145 (Suppl. 2), S165.

Responsible Party:	Cira Fraser PhD, RN, ACNS-BC, Associate Professor, Fraser, Cira, Ph.D., RN, ACNS-BC
ClinicalTrials.gov Identifier:	NCT01111435 History of Changes
Other Study ID Numbers:	Spasticity2010
First Posted:	April 27, 2010
Last Update Posted:	March 5, 2012
Last Verified:	March 2012

Additional relevant MeSH terms:

Muscle Spasticity; Sclerosis; Multiple Sclerosis; Pathologic Processes; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases	Autoimmune Diseases; Immune System Diseases; Muscular Diseases; Musculoskeletal Diseases; Muscle Hypertonia; Neuromuscular Manifestations; Neurologic Manifestations; Signs and Symptoms